Bladder Cancer FAQ
Has the Food and Drug Administration issued any warnings about a link between Actos and bladder cancer?
In June 2011, the FDA warned that patients taking Actos were more likely to be diagnosed with bladder cancer than users of other diabetes medications. The agency added an Actos warning about the drug’s bladder cancer risk to the prescribing information that is issued to doctors, as well as to the medication guide for patients who are prescribed the drug.
How great is the risk of bladder cancer for patients taking Actos?
According to a French study, patients taking Actos are 22% more likely to develop bladder cancer than patients who use other diabetes medications. A second study published in the journal Diabetes Care found that Actos users who take the drug for more than two years are 40% likely than users of other medications to develop bladder cancer.
What are the symptoms of bladder cancer?
According to the Actos FDA warning, early bladder cancer symptoms may include dark colored urine, urinary tract infection, an urgent need to urinate, frequently urinating, pain in the lower back and abdominal pain.
Will the FDA issue an Actos recall?
As of March 2012, the FDA has not announced plans to recall Actos. However, following the publication of a French study concerning the link between Actos and bladder cancer, health officials in France and Germany ordered that sales of the drug be stopped in those countries.
Have any lawsuits against Actos’ manufacturer been filed?
Many patients in the US have filed Actos lawsuits after they were diagnosed with bladder cancer. An Actos class action lawsuit has also been filed in Canada on behalf of patients in that country. Actos lawyers in the US are predicting that 10,000 lawsuits may eventually be filed concerning the diabetes drug.
Am I eligible to file an Actos lawsuit?
If you or a loved one used Actos and were diagnosed with bladder cancer, you may be eligible to file a lawsuit. For a free legal consultation, contact the lawyers at Hissey Kientz, LLP by calling toll-free at 1-866-275-4454, or by filling out the free case evaluation form located on this page.